Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 2,770 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: One cycle Clear all
Enrolling by invitation Phase 4 Interventional

Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?

NCT07148960
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA, Single Agent IV Antibiotic Therapy - MSSA
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 29, 2026, 9:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does Propranolol Attenuate Inflammatory Responses to a Psychological Stressor?

NCT02972554
View directory record Official record
Conditions
Stress, Psychological, Inflammation, Cortisol, Sympathetic Nervous System
Interventions
Propanolol hydrochloride, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 25 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 29, 2026, 9:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy of a Contraceptive Vaginal Ring Delivering Nestorone® and Ethinyl Estradiol

NCT00263341
View directory record Official record
Conditions
Contraception
Interventions
NES/EE CVR
Combination Product
Lead sponsor
Population Council
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
1,135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 29, 2026, 9:52 PM EDT
Terminated Phase 2 Interventional Results available

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

NCT05113966
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Trilaciclib, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Chandler, Arizona • Bakersfield, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 29, 2026, 9:52 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer

NCT01084759
View directory record Official record
Conditions
Prostate Cancer
Interventions
Testosterone injection, Etoposide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 29, 2026, 9:52 PM EDT
Recruiting Phase 2 Interventional

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

NCT06623656
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cemiplimab, Platinum based chemotherapy, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 29, 2026, 9:52 PM EDT
Completed Phase 2 Interventional Results available

Off-the-shelf NK Cells + SCT for Myeloid Malignancies

NCT05115630
View directory record Official record
Conditions
Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
Interventions
Cyclophosphamide, Mesna, Filgrastim, Melphalan, Fludarabine phosphate, Tacrolimus, Mycophenolate mofetil, Total Body Irradiation One Dose
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 29, 2026, 9:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

NCT01453153
View directory record Official record
Conditions
Stage IV Pancreatic Cancer
Interventions
Gemcitabine, PEGPH20, Placebo
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Fayetteville, Arkansas • San Francisco, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 29, 2026, 9:52 PM EDT
Terminated Phase 1 Interventional

Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer

NCT00783172
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Opioid Growth Factor (OGF)
Drug · Biological
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Allentown, Pennsylvania • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 29, 2026, 9:52 PM EDT
Terminated Phase 2 Interventional Results available

Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC

NCT02254681
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Gemcitabine, Cisplatin, low dose radiotherapy
Drug · Radiation
Lead sponsor
Allina Health System
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 29, 2026, 9:52 PM EDT
Recruiting Phase 2 Interventional

sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

NCT05332002
View directory record Official record
Conditions
Gastro-Intestinal Cancer
Interventions
Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Hamilton, New Jersey • Lakewood, New Jersey • Long Branch, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 29, 2026, 9:52 PM EDT
Completed Phase 2 Interventional

VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept

NCT00963053
View directory record Official record
Conditions
Primary Dysmenorrhea
Interventions
VA111913 TS and placebo
Drug
Lead sponsor
Vantia Ltd
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Peoria, Arizona • Austin, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 29, 2026, 9:52 PM EDT
Not listed Not applicable Interventional

Translumbosacral Neuromodulation for FI

NCT03899181
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Translumbosacral Neuromodulation Therapy (TNT), Sham TNT Therapy
Device · Other
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Augusta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 29, 2026, 9:52 PM EDT
Completed Phase 4 Interventional Results available

Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema

NCT02471651
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone intravitreal implant (0.7 mg), Intravitreal anti-VEGF injection
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Bakersfield, California • Oxnard, California • Santa Barbara, California + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 29, 2026, 9:52 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Quantifying Uterine Elastography in Menstruating Women

NCT06816381
View directory record Official record
Conditions
Infertility (IVF Patients), Infertility Assisted Reproductive Technology
Interventions
Shear wave elastography measurements
Device
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 29, 2026, 9:52 PM EDT
Completed Phase 2 Interventional Results available

Edoxaban in Peripheral Arterial Disease

NCT01802775
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
edoxaban, Clopidogrel, Aspirin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 29, 2026, 9:52 PM EDT
Recruiting Phase 1Phase 2 Interventional

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

NCT04520139
View directory record Official record
Conditions
Ovarian Cancer, Cognitive Impairment
Interventions
N-Acetyl-Cysteine, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 29, 2026, 9:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Non-Steroidal Anti-Inflammatory Drug (NSAID) Response and Central Sensitization of Pain in Women With Dysmenorrhea

NCT05900336
View directory record Official record
Conditions
Dysmenorrhea, Menstrual Pain, Non-steroidal Anti-inflammatory Drug
Interventions
Sodium Naproxen, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 29, 2026, 9:52 PM EDT
Terminated Not applicable Interventional Results available

Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel

NCT02491411
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer
Interventions
Dexamethasone, Enzalutamide, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 29, 2026, 9:52 PM EDT
Recruiting Phase 1 Interventional

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

NCT06479811
View directory record Official record
Conditions
Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma, Esthesioneuroblastoma, Olfactory Neuroblastoma, Somatostatin Receptor Positive, Small Cell Lung Cancers, Pheochromocytoma/Paragangliomas, Kidney Cancers, Head and Neck Tumors, Gastrointestinal Neuroendocrine Tumors
Interventions
[212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 29, 2026, 9:52 PM EDT
Recruiting Phase 2 Interventional

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

NCT06441890
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer
Interventions
Paclitaxel, Nab-paclitaxel, Docetaxel, Trastuzumab, Pertuzumab
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 29, 2026, 9:52 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

NCT05092360
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Nemvaleukin and Pembrolizumab Combination, Pembrolizumab, Nemvaleukin, Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, Topotecan, Gemcitabine
Biological · Drug
Lead sponsor
Mural Oncology, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
37
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 29, 2026, 9:52 PM EDT
Completed Phase 2 Interventional

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

NCT02048059
View directory record Official record
Conditions
Breast Cancer, Brain Metastases
Interventions
ANG1005
Drug
Lead sponsor
Angiochem Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
19
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 29, 2026, 9:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nighttime Macronutrient Choice and Combined Resistance and High-intensity Interval Training

NCT01830946
View directory record Official record
Conditions
Obesity
Interventions
Whey Protein, Combined Resistance and High-Intensity Interval training, Casein Protein
Other
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Oct 29, 2026, 9:52 PM EDT